Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?

Magruder, Matthew; Yao, Vincent J H; Rodriguez, Ariel N.; Ng, Mitchell; Sasson, Victor; Erez, Orry

doi:10.1016/j.arth.2023.05.071

Cited by 23 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 52 , 53 Semaglutide use during total knee arthroplasty has been suggested to decrease risk for sepsis, prosthetic joint infections, and readmissions, but may potentially increase risk for myocardial infarction, acute kidney injury, pneumonia, and hypoglycemic events. 54 …”

Section: Glp-1 Receptor Agonists In Other Surgical Specialtiesmentioning

confidence: 99%

Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future

O’Neill,

Wiegmann,

Parrella

et al. 2024

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Summary: Obesity is a major epidemic plaguing American society. Injectable subcutaneous medications initially designed for use in type 2 diabetes management, such as semaglutide and other glucagon-like peptide-1 receptor agonists, are rapidly gaining popularity for their effects on weight. These drugs (Ozempic, Wegovy, Saxenda, and Mounjaro) are ubiquitous on social media and are promoted by celebrities across all demographics. “Ozempic face” and “Ozempic butt” are now mainstream concepts highlighting the morphologic changes that occur with these medications. There is a paucity of literature available on the impact of these medications for plastic surgeons and their patients. As use becomes widespread, it is important for plastic surgeons to understand their indications, contraindications, appropriate perioperative management, and impact on plastic surgery procedures.

show abstract

Section: Glp-1 Receptor Agonists In Other Surgical Specialtiesmentioning

confidence: 99%

Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future

O’Neill,

Wiegmann,

Parrella

et al. 2024

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

show abstract

“…Bariatric surgery may lead to nutrient deficiency, decreased bone density, and increased risks of anemia and fracture 18 . Medical management with semaglutide decreases the weight of patients with obesity 19 and may decrease the risks of sepsis, periprosthetic joint infection, and readmissions but increase the risks of myocardial infarction, acute kidney infection, pneumonia, and hypoglycemic events 20 . These drugs are relatively novel, with minimal data on their clinical impact, preventing an accurate recommendation regarding their usage.…”

Section: Beneficencementioning

confidence: 99%